CARESS in Acute Myocardial Infarction
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The aim of this study conducted in patients with high risk ST-segment elevation AMI admitted to hospitals with no PTCA facilities is to compare the effects on clinical outcome and cost-effectiveness of two reperfusion strategies:
- Fibrinolytic therapy with Abciximab and half-dose Reteplase, with rescue PTCA in case of lack of reperfusion
- Elective referral for “facilitated” PTCA after early administration of Abciximab and half dose of Reteplase
| Condition | Intervention | Phase |
|---|---|---|
|
Myocardial Infarction |
Device: Coronary Angioplasty (PTCA) |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Combined Abciximab Reteplase Stent Study in Acute Myocardial Infarction |
- To compare 30 days incidence of the composite end-point of: mortality, reinfarction and refractory ischemia in the two arms of the study. [ Time Frame: 30 Day ]
- Compare 1 year composite end-point of: mortality, reinfarction, refractory ischemia, hospital readmission because of heart failure in the two arms; [ Time Frame: 1 Year ]
- Compare the resource use at 30 days and 1 year, including days in CCU, MICU or general ward, cost of catheterization and PTCA, drugs, ambulance service during index hospitalization and subsequent hospital admissions for reAMI [ Time Frame: 30 Day and 1 Year ]
- Compare the incidence of in-hospital stroke and bleeding complications in the two arms. [ Time Frame: 30 Day ]
| Enrollment: | 600 |
| Study Start Date: | May 2003 |
| Study Completion Date: | March 2007 |
All patients with ST-segment elevation AMI admitted within 12 hours from symptoms onset will be screened to enter in this study. Data of patients with ST-segment elevation AMI within 12 hours from symptoms onset who do not meet the inclusion criteria or do not sign the informed consent form are entered into a dedicated registry.
Eligibility| Ages Eligible for Study: | up to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- ECG with ST-elevation (≥ 1mm in at least 2 ECG limb leads or ≥ 2 mm in 2 contiguous precordial leads) AMI within <12 hours from symptoms onset fulfilling 1 or more of the following criteria of “high risk”:
- Summation of ST-segment elevation or depression ≥ 15 mm in all 12 electrocardiographic leads or new onset complete left bundle branch block;
- Previous myocardial infarction (Q- and non Q-wave);
- Killip Class 2 or 3;
- LV ejection fraction at transthoracic ultrasound < 40%.
Exclusion Criteria:
- Inability to provide informed consent;
- Age > 75 years
- CABG or PCI procedure in past history involving the infarct-related artery;
- Participation in another study with any investigational drug or device within the previous 30 days;
- Concomitant non-cardiac disease likely to limit long-term prognosis (e.g. cancer);
- Cardiogenic shock (hypotension with Systolic Blood Pressure (SBP) < 90 mmHg and tachycardia > 100 beats / min, not due to hypovolemia and requiring inotropic support or balloon counterpulsation);
- Need for concomitant major surgery (e.g. valve surgery or resection of aortic or left ventricular aneurysm, carotid endarterectomy, abdominal aortic aneurysm surgery, congenital heart disease etc);
- Severe hepatic disease;
- Patients with acute or chronic renal impairment (serum creatinine > 2.0 mg % or 200 mg/l or creatinine clearance < 30 ml/min);
- Transmural MI in different location within the previous week;
- Previous administration of thrombolytics within 7 days;
- Intolerance or contraindications to ASA or Clopidogrel;
- Known leucopenia, defined as a leukocyte count of < 3.500 White Blood Cells (WBC)/ml
- Known neutropenia, defined as < 1000 neutrophils / ml;
- Known thrombocytopenia (< 100.000 platelets / ml );
- Documented active peptic ulcer or upper gastrointestinal bleeding within the previous 6 months;
- Previous hemorrhagic stroke;
- Previous ischemic cerebrovascular event within 3 months;
- Intracranial neoplasm;
- Recent major surgery at risk of bleeding;
- Episodes of uncontrolled hypertension (> 180/110 mmHg despite treatment) in past 2 years;
- Administration of oral anticoagulants within the previous 7 days unless INR ≤ 1.2;
- Severe recent trauma;
- Known or possible pregnancy;
- Absence of suitable vascular access (diffuse peripheral arterial disease);
- Basal ECG changes which make identification of ST-segment elevation impossible (i.e.: ventricular activation from artificial pacemaker, etc.).
Contacts and Locations
Show 85 Study Locations| Principal Investigator: | Leonardo Bolognese, MD, Ph D | Ospedale San Donato - Arezzo Italy |
| Principal Investigator: | Gabriel P. Steg, MD. Ph D | Hopital Bichat - Paris France |
| Principal Investigator: | Darius Dudek, MD, Ph D | Jagellonian University Krakow Poland |
| Study Chair: | Carlo Di Mario, MD | Royal Brompton and Harefield Hospital - London UK |
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00220571 History of Changes |
| Other Study ID Numbers: | IIT(IT) H4S-IT-O038, 2003OE001B |
| Study First Received: | September 13, 2005 |
| Last Updated: | July 2, 2007 |
| Health Authority: | Italy: Ministry of Health France: Ministry of Health Poland: Ministry of Health |
Keywords provided by Società Italiana di Cardiologia Invasiva:
|
AMI stent PTCA |
abciximab reteplase combo therapy |
Additional relevant MeSH terms:
|
Infarction Myocardial Infarction Ischemia Pathologic Processes Necrosis Myocardial Ischemia Heart Diseases Cardiovascular Diseases Vascular Diseases Reteplase |
Abciximab Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Cardiovascular Agents Therapeutic Uses Hematologic Agents Platelet Aggregation Inhibitors Anticoagulants |
ClinicalTrials.gov processed this record on May 23, 2013